[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcatheter-arterial-chemoembolization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcatheter-arterial-chemoembolization":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100572984","tace-combined-with-lenvatinib-and-pd-1-inhibitor-for-ruptured-hepatocellular-carcinoma-100572984",false,"NCT06740370","TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma","TACE Combined With Lenvatinib and PD-1 Inhibitor for Spontaneous Rupture of Hepatocellular Carcinoma: a Prospective Multicenter Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of hemostasis in the enhanced CT scan;\n3. integrity of the tumor is disrupted and there is hematoma around the liver;\n4. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;\n5. transarterial artery chemoembolization (TACE) as local therapy;\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. recurrent HCC;\n2. non-ruptured HCC;\n3. Lenvatinib and PD-1 inhibitor treated with as second systemic therapy;\n4. age \\\u003C 18 years or \\> 75 years;\n5. HCC with more than five metastases;\n6. History of hepatic encephalopathy and gastrointestinal bleeding\n7. life expectancy less than 3 months.","ALL","18 Years","75 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved. Then minimally therapy like transcatheter arterial chemoembolization (TACE) could effectively stanch the ruptured tumor and bleeding vessels. Then TACE combined the Lenvatinib and PD-1 inhibitor for this subtype HCC could effectively inhibit the tumor and improve the prognosis.",[27,28,29,30],"Hepatocellular Carcinoma","Transcatheter Arterial Chemoembolization","Anti-PD1 Antibody","Lenvatinib",[32,33,30,34,35,36],"ruptured hepatocellular carcinoma","TACE","Tislelizumab","Sintilimab","Camrelizumab","RECRUITING","2025-08-10",{"date":40,"type":41},"2025-08-14","ACTUAL",{"date":43,"type":41},"2024-12-13",{"date":45,"type":21},"2026-08-30",{"name":47,"class":48},"Sun Yat-sen University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":77,"locationsCount":49},"100401868","comparison-of-efficacy-in-sbrt-of-large-hcc-with-or-without-tace-100401868","NCT04512846","Comparison of Efficacy in SBRT of Large HCC With or Without TACE","Comparison of Efficacy in Stereotactic Body Radiation Therapy (SBRT) of Large Hepatocellular Carcinoma (5-10 cm) With or Without Transcatheter Arterial Chemoembolization (TACE)","Inclusion Criteria:\n\n* primary HCC diagnosed by a surgeon and\u002For radiologist and oncologist according to the international guidelines for the management of HCC or by pathology\n* single lesion and longest tumor diameter were 5-10cm;\n* CP-A or B classification;\n* Eastern Cooperative Oncology Group (ECOG) score 0-1;\n* distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm\n* unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc.\n* rejecting other therapies such as resection, liver transplantation, etc.\n* platelet count≥50 × 109\u002FL, white blood count≥1.5 × 109\u002FL;\n* patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.\n\nExclusion Criteria:\n\n* tumor thrombus;\n* lymph node involvement;\n* extrahepatic metastasis.","30 Years","80 Years",{"count":60,"type":21},100,"OBSERVATIONAL","The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.",[64,65,28],"Large HCC Patients","Stereotactic Body Radiation Therapy",[67,68,69,70],"CyberKnife","SBRT","large HCC","prognosis","2023-06-24",{"date":73,"type":41},"2023-06-27",{"date":75,"type":41},"2020-08-01",{"date":45,"type":21},{"name":78,"class":48},"Beijing 302 Hospital"]